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More on Subgroup Analyses in Clinical Trials
To the Editor: With regard to the article by 
Wang et al. (Nov. 22 issue), it is increasingly rec-
ognized that subgroup analyses in clinical trials 
are sometimes misused and require appropriate 
presentation and cautious interpretation.1,2 How-
ever, we would recommend that one type of sub-
group analysis (in large “positive” trials or meta-
analyses) be performed more often. That is, from 
a prognostic model, one categorizes patients into 
several ordered risk groups and estimates the ab-
solute risk reduction in each group. For instance, 
the Third Randomized Intervention Treatment of 
Angina (RITA-3) trial,3 involving patients with 
acute coronary syndromes, showed an overall re-
duction in the risk of myocardial infarction or 
death associated with an invasive strategy as com-
pared with conservative management. Such a risk-
stratified subgroup analysis then usefully clarified 
that this benefit was mainly in patients at high 
risk for myocardial infarction or death.
In general, such an approach can be an impor-
tant aid for clinical practice, so that for any spe-
cific patient, one can judge the absolute benefit of 
a new treatment (set against the absolute risk of 
side effects, as well as costs if relevant) and decide 
whether the treatment is warranted for that pa-
tient. This approach is also applicable when, with 
regard to relative risk, there is no evidence of sub-
group interactions with treatment. The question 
of whether prasugrel is preferable to clopidogrel 
in acute coronary syndromes4 is an interesting 
example; it may be that the absolute benefit of 
the reduced risk of ischemic events outweighs the 
increased risk of bleeding only for high-risk 
patients.
Similarly, if the absolute risk of myocardial in-
farction due to rofecoxib (Vioxx) had been prop-
erly quantified in appropriate risk-stratified sub-
group analyses, the benefits of pain relief and 
reduced gastrointestinal bleeding might have been 
more clearly seen to outweigh the low absolute risk 
of myocardial infarction in a substantial propor-
tion of patients, thus permitting the continued 
prescription of rofecoxib with appropriately re-
strictive labeling.
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The Authors Reply: We agree with Pocock and 
Lubsen about the value of subgroup analyses in 
examining whether the absolute risk reduction var-
ies across a baseline risk categorization. Howev-
er, obtaining and applying such information in 
practice pose challenges. Whenever possible, the 
algorithm for forming risk categories should be 
determined from external data.1 When a multi-
variate regression model is used to form risk cat-
egories that are based on the same data used to 
evaluate the new treatment, it is preferable to 
build the model only with the use of data from 
the subjects in the control group. Risk categories 
suggested by observed treatment-group differ-
ences are prone to bias and should be avoided. 
It is also important to consider the robustness 
of the conclusions of such analyses with regard 
to different choices of risk categories. For exam-
ple, patients in the RITA-3 trial were initially clas-
sified into four categories (1, 2, 3, and 4) and then 
further classified into five categories by splitting 
category 4 into two groups (4a and 4b).2 The five-
category classification suggests relatively small 
absolute treatment differences in all groups ex-
cept 4b (19%), whereas the four-level categori-
zation suggests a large effect only in category 
4 (13%), which might lead to a different treatment 
strategy for patients in category 4a. Furthermore, 
the uncertainty in the estimated risk reduction 
within each risk group needs to be considered. 
For example, in the RITA-3 trial, the estimated risk 
reduction for category 4a is 4.1%, but the corre-
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sponding 95% confidence interval ranges from a 
16.7% reduction to an 8.5% increase. Finally, 
within-level comparisons should be preceded by 
evidence of the heterogeneity of treatment effect 
based on an interaction test oriented to differences 
in absolute risk.
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Dual Inheritance of Sudden Death from Cardiovascular Causes
To the Editor: The long-QT syndrome and cat-
echolaminergic polymorphic ventricular tachycar-
dia are the most common inherited cardiac chan-
nelopathies.1 Although the disease mechanisms 
for these two disorders differ, the resulting ar-
rhythmias are similar, and both are triggered by 
sympathetic stimulation.2,3 We identified the co-
existence of the two diseases in one family.
A family with a history of recurrent sudden 
death was studied. During the past 30 years, nine 
members have died suddenly between 7 and 40 
years of age. A borderline QT interval corrected 
for heart rate (QTc) of 450 msec in one asymp-
tomatic relative (identified as V-1 in Fig. 1) was 
noted. Genetic testing revealed a heterozygous 
mutation in KCNQ1 (1343delC, p.P448fsX465), con-
firming the diagnosis of the long-QT syndrome 
type 1.4 A diagnostic molecular test for this muta-
tion was therefore performed in all consenting fam-
ily members.
Subsequently, one girl (identified as V-13 in 
Fig. 1) who did not inherit the KCNQ1 mutation 
died suddenly at 13 years of age. In addition, sev-
eral other noncarriers had symptoms such as 
syncope. Resting electrocardiograms (ECGs) from 
these family members did not show any abnor-
malities. During exercise stress testing, prema-
ture ventricular beats were detected. A second 
familial disorder was suspected. Therefore, fam-
ily members were evaluated to identify members 
meeting the following criteria: symptoms or sud-
den death during sympathetic stimulation, nor-
mal findings on a resting ECG, the absence of 
structural cardiac abnormalities, and premature 
ventricular beats during exercise.
A pedigree analysis indicated that the second 
36p6
AUTHOR:
FIGURE:
JOB:
4-C
H/T
RETAKE
SIZE
ICM
CASE
EMail Line
H/T
Combo
Revised
AUTHOR, PLEASE NOTE: 
Figure has been redrawn and type has been reset.
Please check carefully.
REG F
Enon
1st
2nd
3rd
Beckmann
1 of 1
05-08-08
ARTIST: ts
35819 ISSUE:
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
+
−
+
−
+
−
+
−
+
+
−
+
−
−
+
−
+
+
−
+
+
+
−
+
−
+
−
+
−
+
−
+
−
−
−
−
−
I
II
III
IV
V
1 2
2
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 2928 30 31 32 33 34 35 36 37 38 39 40 41 42 43 441
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
31 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2221 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38
3 4 5 6
1 2
Figure 1. Key Extract of the Pedigree of Five Generations of a Family with the Long-QT Syndrome and Catecholaminergic Polymorphic  
Ventricular Tachycardia.
Circles indicate female family members, squares male family members, solid symbols clinically affected family members, and open sym-
bols clinically unaffected family members. Deceased family members are indicated by slashes through the symbols. Symbols with 
squares within squares and squares within circles indicate obligate carriers. Diamonds indicate persons for whom sex was unknown. 
The upper symbol below a circle or square indicates the presence (+) or absence (−) of the KCNQ1 mutation, and the lower symbol indi-
cates the presence (+) or absence (−) of the RYR2 mutation in persons who underwent DNA testing. The boxed area is the part of the 
family in which the KCNQ1 mutation was introduced by marriage.
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